Security key
037326105
- Security type / class
- Equity / Common Stock
- Total 13F shares
- 20,391,503
- Total 13F value
- $417,920,110
- Share change
- +459,392
- SEC-reported price per share
- $20.49
- Number of holders
- 51
- Value change
- +$9,592,150
- Number of buys
- 31
- Number of sells
- 12
- Shares outstanding
- 36,076,317
Holder snapshot
6 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q4 2023
Institutions
51
Top holders
10
ANTX full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q3 2025
AN2 Therapeutics, Inc. SEC filings
AN2 Therapeutics, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 037326105
Recent filing periods:
Ownership snapshot
Top reported holders of ANTX - AN2 Therapeutics, Inc. - Common Stock (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
RA CAPITAL MANAGEMENT, L.P.
Disclosed value leader
RA CAPITAL MANAGEMENT, L.P.
Comparable rows
15/15
Latest evidence
30 Sep 2023
13F
Lead comparable stake: 15%
Showing 1-6 of 15 holder rows.
Quick read
RA CAPITAL MANAGEMENT, L.P. leads the comparable SEC ownership view at 15%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens RA CAPITAL MANAGEMENT, L.P.'s linked filing trail.
Comparable ownership
Top 5
RA CAPITAL MANAGEMENT, L.P.
15%
TCG Crossover Management, LLC
7.4%
BVF INC/IL
4.3%
CITADEL ADVISORS LLC
4.3%
Janus Henderson Group Ltd.
3.9%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. |
13F
Company
|
15%
|
$89,264,824
5,551,295 shares
|
— | 30 Sep 2023 |
| TCG Crossover Management, LLC |
13F
Company
|
7.4%
|
$43,065,600
2,678,209 shares
|
— | 30 Sep 2023 |
| BVF INC/IL |
13F
Company
|
4.3%
|
$25,148,525
1,563,963 shares
|
— | 30 Sep 2023 |
| CITADEL ADVISORS LLC |
13F
Company
|
4.3%
|
$25,029,356
1,556,552 shares
|
— | 30 Sep 2023 |
| Janus Henderson Group Ltd. |
13F
Company
|
3.9%
|
$22,146,816
1,388,950 shares
|
— | 30 Sep 2023 |
| Frazier Life Sciences Management, L.P. |
13F
Company
|
3.8%
|
$22,333,335
1,388,889 shares
|
— | 30 Sep 2023 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q4 2023
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
51
Shares
20,391,503
Rows available
51
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q4 2023 vs Q1 2026 Across Filers
Q1 2026 holders
52
Q4 2023 holders
51
Holder diff
-1
| Investor | Q1 2026 Shares | Q4 2023 Shares | Share Diff | Share Chg % | Q1 2026 value | Q4 2023 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend